Browse our 650+ Publications​

Latest Publications

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

Coffey DG, et al.
Nature Communications
October 2023
Authors and Affiliates
David G Coffey 1,2, Francesco Maura 3, Edgar Gonzalez-Kozlova 4, J Javier Diaz-Mejia 5, Ping Luo 5, Yong Zhang 6, Yuexin Xu 7, Edus H Warren 7, Travis Dawson 4, Brian Lee 4, Hui Xie 4, Eric Smith 8, Amanda Ciardiello 9, Hearn J Cho 4,10, Adeeb Rahman 4, Seunghee Kim-Schulze 4, Benjamin Diamond 3, Alexander Lesokhin 9, Dickran Kazandjian 3, Trevor J Pugh 5,11,12, Damian J Green 7, Sacha Gnjatic 4, Ola Landgren 13; 1 Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. davidcoffey@miami.edu. 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. davidcoffey@miami.edu. 3 Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. 4 Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. 6 Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. 7 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8 Dana-Farber Cancer Institute, Boston, MA, USA. 9 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Multiple Myeloma Research Foundation, Norwalk, USA. 11 Ontario Institute for Cancer Research, Toronto, ON, Canada. 12 Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. 13 Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. col15@miami.edu.

Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

Xu-Monette ZY, et al.
Clinical Cancer Research
October 2023
Authors and Affiliates
Zijun Y Xu-Monette 1, Yong Li 2, Thomas Snyder 3, Tiantian Yu 4, Tingxun Lu 5, Alexandar Tzankov 6, Carlo Visco 7, Govind Bhagat 8, Wenbin Qian 9, Karen Dybkaer 10, April Chiu 11, Wayne Tam 12, Youli Zu 13, Eric D Hsi 14, Fredrick B Hagemeister 15, Yingjun Wang 16, Heounjeong Go 17, Maurilio Ponzoni 18, Andrés J M Ferreri 19, Michael B Moller 20, Benjamin M Parsons 21, Xiangshan Fan 22, J Han van Krieken 23, Miguel A Piris 24, Jane N Winter 25, Qingyan Au 26, Ilan Kirsch 27, Mingzhi Zhang 28, John Shaughnessy 29, Bing Xu 30, Ken H Young 31; 1 Duke University, Durham, North Carolina, United States. 2 Baylor College of Medicine, Houston, United States. 3 Adaptive Biotechnologies (United States), Seattle, United States. 4 Second Affiliated Hospital of Nanchang University, Nanchang, China. 5 Duke University, Durham, United States. 6 University of Basel, Hospital, Basel, Switzerland. 7 University of Verona, Verona, Italy. 8 Columbia University Medical Center, New York, NY, United States. 9 Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China. 10 Aalborg University Hospital, Aalborg,, Denmark. 11 Mayo Clinic, Rochester, MN, United States. 12 Weill Cornell Medicine, New York, NY, United States. 13 Houston Methodist, HOUSTON, Texas, United States. 14 Wake Forest University School of Medicine, Winston-Salem, NC, United States. 15 The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 16 The University of Texas MD Anderson Cancer Center, United States. 17 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (South), Republic of. 18 San Raffaele Scientific Institute, Milano, Italy. 19 IRCCS San Raffaele Scientific Institute, Milano, MI, Italy. 20 Odense University Hospital, Odense, Denmark. 21 Gundersen Lutheran Health System, La Crosse, WI, United States. 22 First Affiliated Hospital of Anhui Medical University, China. 23 Radboud university medical centre, Nijmegen, Netherlands. 24 Fundacion Jimenez Diaz, Madrid, Madrid, Spain. 25 Feinberg School of Medicine, Northwestern University, Chicago, IL, United States. 26 NeoGenomics, United States. 27 Adaptive Biotechnologies (United States), Seattle, WA, United States. 28 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. 29 University of Arkansas for Medical Sciences, Little Rock, AR, United States. 30 First Affiliated Hospital of Xiamen University, Xiamen, China. 31 Duke University, Durham, NC, United States.

CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis

Nayyar N, et al.
Clinical Cancer Research
October 2023
Authors and Affiliates
Naema Nayyar 1, Magali A de Sauvage 1, Jane Chuprin 2, Emily M Sullivan 3, Mohini Singh 1, Consuelo Torrini 4, Britney S Zhang 3, Sushobhana Bandyopadhyay 2, Keith A Daniels 2, Christopher Alvarez-Breckenridge 5, Ashish Dahal 6, Michael A Brehm 2, Priscilla K Brastianos 7; 1 Massachusetts General Hospital, Boston, MA, United States. 2 University of Massachusetts Chan Medical School, Worcester, MA, United States. 3 Massachusetts General Hospital, Boston, United States. 4 Massachusetts General Hospital, BOSTON, United States. 5 The University of Texas MD Anderson Cancer Center, Houston, United States. 6 Harvard Medical School & Massachusetts General Hospital, Boston, MA, United States. 7 Massachusetts General Hospital, Boston, Massachusetts, United States.

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase 1b Trial

Nawrocki ST, et al.
Clinical Cancer Research
October 2023
Authors and Affiliates
Steffan T Nawrocki 1, Julian Olea 2, Claudia Villa Celi 3, Homa Dadrastoussi 4, Kaijin Wu 4, Denice Tsao-Wei 5, Anthony Colombo 6, Matthew Coffey 7, Eduardo Fernandez Hernandez 8, Xuelian Chen 9, Gerard J Nuovo 10, Jennifer S Carew 11, Ann F Mohrbacher 2, Paul Fields 12, Peter Kuhn 2, Imran Siddiqi 13, Akil Merchant 14, Kevin R Kelly 4; 1 University of Arizona Cancer Center, Tucson, AZ, United States. 2 University of Southern California, Los Angeles, CA, United States. 3 Capital Health, Hamilton, NJ, United States. 4 USC Norris Comprehensive Cancer Center, Los Angeles, CA, United States. 5 USC Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California, United States. 6 Cedars-Sinai Medical Center, Los Angeles, CA, United States. 7 Oncolytics Biotech (Canada), Calgary, Alberta, Canada. 8 USC Norris Cancer Hospital, Los Angeles, CA, United States. 9 University of Southern California, LOS ANGELES, California, United States. 10 The Ohio State University, Columbus, OH, United States. 11 University of Arizona Cancer Center, Tucson, Arizona, United States. 12 Adaptive Biotechnologies (United States), Seattle, WA, United States. 13 University of Southern California Keck School of Mdicine, Los Angeles, CA, United States. 14 Cedars-Sinai Medical Center, Los Angeles, United States.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.

Bahlis, N, et al.
Nature Medicine
October 2023
Authors and Affiliates
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P Chu, Andrew Dalovisio, Michael Sebag, Alexander M Lesokhin

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

Costa L, et al.
Lancet Haematology
September 2023
Authors and Affiliates
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt, Kelly N Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D'Souza, Aric C Hall, Pamela Hardwick, James Omel, Robert F Cornell, Parameswaran Hari, Natalie S Callander

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.

Kubicki T, et al.
British Journal of Haematology
September 2023
Authors and Affiliates
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Jan Maciej Zaucha, Damian Mikulski, Olga Czabak, Oscar B Lahoud, Andrew Stefka, Benjamin A Derman, Andrzej J Jakubowiak.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Epstein-Peterson ZD, et al.
Haematologica
August 2023
Authors and Affiliates
Zachary D. Epstein-Peterson1 , Esther Drill2 , Umut Aypar3 , Connie Lee Batlevi1 , Philip Caron1 , Ahmet Dogan3 , Pamela Drullinsky1 , John Gerecitano1 , Paul A. Hamlin1 , Caleb Ho3 , Allison Jacob4 , Ashlee Joseph1 , Leana Laraque1 , Matthew J. Matasar1 , Alison J. Moskowitz1 , Craig H. Moskowitz1 , Chelsea Mullins4 , Colette Owens1 , Gilles Salles1 , Heiko Schöder5 , David J. Straus1 , Anas Younes1 , Andrew D. Zelenetz1 , and Anita Kumar1 1 Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center 2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center 3Department of Pathology, Memorial Sloan Kettering Cancer Center 4Adaptive Biotechnologies, Seattle, WA, USA 5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

Vos JL, et al.
Nature Medicine
August 2023
Authors and Affiliates
Joris L Vos 1, Bharat Burman 2, Swati Jain 1, Conall W R Fitzgerald 1, Eric J Sherman 2, Lara A Dunn 2, James V Fetten 2, Loren S Michel 2, Anuja Kriplani 2, Kenneth K Ng 2, Juliana Eng 2, Vatche Tchekmedyian 3, Sofia Haque 4, Nora Katabi 5, Fengshen Kuo 1, Catherine Y Han 1, Zaineb Nadeem 1, Wei Yang 1, Vladimir Makarov 6, Raghvendra M Srivastava 6, Irina Ostrovnaya 7, Manu Prasad 1, Charlotte L Zuur 8,9, Nadeem Riaz 10, David G Pfister 2, Christopher A Klebanoff 2,11,12, Timothy A Chan 6, Alan L Ho 13, Luc G T Morris 14; 1 Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Department of Medicine, Maine Medical Center-Tufts University School of Medicine, Portland, ME, USA. 4 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Center for Immunotherapy and Precision Immuno-oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. 7 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 9 Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands. 10 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 11 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hoa@mskcc.org. 14 Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.
Previous Next